ArticleDrug design, development and therapy2016
Investigation of in vivo potential of scorpion venom against skin tumorigenesis in mice via targeting markers associated with cancer development.
Article in Drug design, development and therapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 48 citations in OpenAlex.
- Nanocarrier-based intranasal drug delivery for enhanced neurological disorders treatment.Drug delivery and translational research · 2026Review
- Therapeutic Potential of Scorpion Venom Proteins: Innovations in Cancer Treatment and Future Directions.Current drug targets · 2026Review
- Review
- Harnessing the potency of scorpion venom-derived proteins: applications in cancer therapy.Bioresources and bioprocessing · 2024Review
- Article
- Discovery of Leptulipin, a New Anticancer Protein from theIranian Scorpion,Molecules (Basel, Switzerland) · 2022Article
- Voltage-Gated KFrontiers in pharmacology · 2020Review
- Pleiotropic Anticancer Properties of Scorpion Venom Peptides:Drug design, development and therapy · 2020Review
- Pharmacokinetics and Biodistribution of Rhopalurus junceus Scorpion Venom in Tumor-Bearing Mice after Intravenous and Oral AdministrationIranian biomedical journal · 2019Article
- Analgesic-antitumor peptide inhibits angiogenesis by suppressing AKT activation in hepatocellular carcinoma.Molecular and cellular biochemistry · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer is the leading cause of morbidity and mortality all over the world in spite of the advances made in its management. In this study, we investigated the in vivo anti-tumorigenic potential of the venom obtained from a medically important scorpion species
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.